Global pharmaceutical major Strides Arcolab today said its Singapore-based wholly owned subsidiary Strides Pharma Global has been awarded 'International Headquarters Status' by the Singapore Economic Development Board (EDB).
Strides Pharma Global proposes to carry out activities for its international business, including business development and planning, sales and marketing, intellectual property management, global supply chain management and global regulatory affairs.
"Singapore was selected as the International headquarters after assessing various options. Strides Pharma Global, Singapore will also be building a new manufacturing facility in Singapore in the next couple of years with focus on the regulated and South East Asia markets," Strides Pharma Global CEO Mohan Kumar said in a statement here.
